Genprex, Inc. (NASDAQ:GNPX) Short Interest Update

Genprex, Inc. (NASDAQ:GNPX) saw a significant decline in short interest in March. As of March 15th, there was short interest totalling 333,600 shares, a decline of 47.3% from the February 28th total of 633,100 shares. Based on an average daily volume of 1,830,000 shares, the days-to-cover ratio is presently 0.2 days. Currently, 4.0% of the shares of the company are sold short.

Genprex Stock Performance

NASDAQ GNPX traded down $0.07 on Friday, hitting $0.27. The stock had a trading volume of 3,612,556 shares, compared to its average volume of 3,047,860. Genprex has a 52-week low of $0.25 and a 52-week high of $4.09. The firm has a 50-day moving average of $0.45 and a 200-day moving average of $0.81.

Hedge Funds Weigh In On Genprex

An institutional investor recently raised its position in Genprex stock. Geode Capital Management LLC increased its position in Genprex, Inc. (NASDAQ:GNPX) by 368.1% during the fourth quarter, according to the company in its most recent filing with the Securities and Exchange Commission (SEC). The institutional investor owned 76,045 shares of the company’s stock after purchasing an additional 59,798 shares during the period. Geode Capital Management LLC owned approximately 0.89% of Genprex worth $65,000 at the end of the most recent reporting period. Hedge funds and other institutional investors own 14.05% of the company’s stock.

Genprex Company Profile

Genprex, Inc, a clinical-stage gene therapy company, focuses on developing gene-based therapies for patients with cancer and diabetes in the United States. The company's lead product candidate is REQORSA (GPX-001), which is in preclinical trials to treat non-small cell lung cancer and small cell lung cancer; and GPX-002, which is in preclinical trials to treat type 1 and type 2 diabetes.